Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia

  • N. Nakamura
  • T. Hamazaki
  • M. Ohta
  • K. Okuda
  • M. Urakaze
  • S. Sawazaki
  • K. Yamazaki
  • A. Satoh
  • R. Temaru
  • Y. Ishikura
  • M. Takata
  • M. Kishida
  • M. Kobayashi
Original

Abstract

HMG-CoA reductase inhibitors reduce serum total cholesterol concentrations and the risk of coronary heart disease in patients with hypercholesterolemia. Recently, it has been reported that patients with combined hyperlipidemia are also at risk of coronary heart disease. However, HMG-CoA reductase inhibitor therapy alone does not sufficiently reduce serum triglyceride concentrations. Epidemiological and clinical evidence has shown that fish oil can lower plasma lipid levels, especially triglycerides. Consequently, we investigated the effects of the combination of HMG-CoA reductase inhibitors and eicosapentaenoic acid, a major component of fish oil, on hyperlipidemia. We administered 900–1,800 mg/day of the ethyl ester of eicosapentaenoic acid to patients with hyperlipidemia who had been treated with HMG-CoA reductase inhibitors for 30±6 months (means±SE). Serum total cholesterol and triglyceride concentrations were significantly decreased 3 months after the administration of eicosapentaenoic acid (from 5.63±0.23 mmol/l to 5.02±0.20 mmol/l,P<0.05; from 2.07±0.41 mmol/l to 1.08±0.17 mmol/l,P<0.01, respectively). Serum high-density lipoprotein-cholesterol concentrations were significantly increased after the treatment (from 1.23±0.12 mmol/l to 1.34±0.13 mmol/l,P<0.05). Plasma eicosapentaenoic acid concentrations and the ratio to arachidonic acid in plasma were also significantly increased 3 months after the treatment (from 101.9±8.1 mg/l to 181.8±23.9 mg/l,P<0.001; from 0.640±0.075 to 1.211±0.170,P<0.001, respectively). These results suggested that the combination therapy of HMG-CoA reductase inhibitors and eicosapentaenoic acid was effective for patients with hyperlipidemia.

Key words

Arachidonic acid Eicosapentaenoic acid HMG-CoA reductase inhibitor Remnant-like particles cholesterol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cholesterol Adult Treatment Panel Report. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148:36.Google Scholar
  2. 2.
    Brown G, Albert JJ, Fishers LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289.PubMedGoogle Scholar
  3. 3.
    The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.Google Scholar
  4. 4.
    Shepherd J, Stuart M, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, Mckillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301.PubMedCrossRefGoogle Scholar
  5. 5.
    Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544.PubMedCrossRefGoogle Scholar
  6. 6.
    Tobert JA. Efficacy and long term adverse effect pattern on lovastatin. Am J Cardiol 1988; 62:28.CrossRefGoogle Scholar
  7. 7.
    Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.PubMedCrossRefGoogle Scholar
  8. 8.
    Gibson RA. The effect of diet containing fish and fish oil on disease risk factors in humans. Aust N Z J Med 1988; 18:713.PubMedGoogle Scholar
  9. 9.
    Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 318:549.PubMedGoogle Scholar
  10. 10.
    Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30:785.PubMedGoogle Scholar
  11. 11.
    Contacos C, Barter PJ, Sullivian DR. Effect of pravastatin andθ-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscl Thromb 1993; 13:1755.PubMedGoogle Scholar
  12. 12.
    Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223:53.PubMedCrossRefGoogle Scholar
  13. 13.
    Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simavastatin in patients with combined hyperlipidemia. Am J Cardiol 1997; 80:797.PubMedCrossRefGoogle Scholar
  14. 14.
    Reaven P. The role of dietary fat in LDL oxidation and atherosclerosis. Nutr Metab Cardiovasc 1996; 6:57.Google Scholar
  15. 15.
    Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen J-B, Ingebretsen OC. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Intern Med 1998; 243:163.PubMedCrossRefGoogle Scholar
  16. 16.
    Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33:369.PubMedGoogle Scholar
  17. 17.
    Sakata K, Miho N, Shirotani M, Yoshida H, Takada Y, Takada A. Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis 1998; 136:225.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakamura N, Hamazaki T, Kobayashi M, Ohta M, Okuda K. Effects of eicosapentaenoic acids on remnant-like particles cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus. In Vivo 1998; 12:311.PubMedGoogle Scholar
  19. 19.
    Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; II:757.CrossRefGoogle Scholar
  20. 20.
    Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovberg V, Arbogast P, Smith H, Kushi LH, Cobb LA, Copass MK, Psaty BM, Lemaitre R, Retzlaff B, Childs M, Knopp RH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274:1363.PubMedCrossRefGoogle Scholar
  21. 21.
    Nakamura N, Hamazaki T, Jokaji H, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res 1998; 28:192.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • N. Nakamura
    • 1
  • T. Hamazaki
    • 2
  • M. Ohta
    • 3
  • K. Okuda
    • 3
  • M. Urakaze
    • 1
  • S. Sawazaki
    • 1
  • K. Yamazaki
    • 1
  • A. Satoh
    • 1
  • R. Temaru
    • 1
  • Y. Ishikura
    • 1
  • M. Takata
    • 1
  • M. Kishida
    • 1
  • M. Kobayashi
    • 1
  1. 1.The First Department of Internal MedicineToyama Medical and Pharmaceutical UniversityToyama-city, ToyamaJapan
  2. 2.The Department of Clinical Application, Research Institute of Wakan-YakuToyama Medical and Pharmaceutical UniversityToyama-city, ToyamaJapan
  3. 3.Department of Internal MedicineTakaoka City HospitalTakaoka-city, ToyamaJapan

Personalised recommendations